

A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major CV events in Patients with Coronary or Peripheral Artery Disease (COMPASS- CV Outcomes for People using Anticoagulation Strategies)

Status : Ongoing

Sponsor/Support : Bayer & Population Health Research Institute (PHRI)

Duration : 2013 - 2018

Principle Investigator : Prof. Dato' Dr. Khalid Yusoff

Co-Investigator/s : Dr. Rizmy Najme Khir, Dr. Lim Chiao Wen

Study Manager : Sazreza Shahadan

Study Member : Saleha Baharuddin

Venue : Selayang Campus